Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-PLEX1000 is an investigational antibiotic-eluting bone graft product developed by PolyPid for the prevention and treatment of bone infections, particularly in the context of severe open long bone fractures (Gustilo type I-IIIB). The product utilizes PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology to provide a controlled, extended release of the antibiotic doxycycline hyclate directly at the surgical site over several weeks. The antibiotic is paired with beta-tricalcium phosphate (beta-TCP) granules, which serve as an osteoconductive scaffold to support bone healing and regeneration. This local delivery approach aims to achieve high antimicrobial concentrations at the infection site while maintaining low systemic exposure, thereby reducing the risk of deep bone infections and potentially accelerating bone healing time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-PLEX1000.